Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-Resistant
 Staphylococcus aureus
 , Vancomycin-Resistant
 Enterococcus faecium
 , and Methicillin-Resistant
 Staphylococcus aureus
 Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations

Akins, Ronda L.; Rybak, Michael J.

doi:10.1128/aac.45.2.454-459.2001

Cited by 177 publications

(136 citation statements)

References 18 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…It appears that vancomycin exposure per se can induce low-level daptomycin resistance or daptomycin heteroresistance (131,283,293,348); however, these changes appear to be strain specific and may be unstable (283). Data from in vitro and animal studies suggest that daptomycin may have a lower rate of in vitro killing of hVISA than against VSSA (175); however, daptomycin retains bactericidal activity against hVISA and VISA (2,40,196,283). hVISA and VISA are generally susceptible to daptomycin by MIC testing (299), with an MIC range from 0.125 to 1 g per ml against 50 hVISA/ VISA strains in one study.…”

Section: Potentially Active Antimicrobials Currently Availablementioning

confidence: 99%

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

et al. 2010

View full text Add to dashboard Cite

SUMMARY The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these strains, clinicians treating patients with infections due to these strains, and researchers attempting to understand the resistance mechanisms. Recent data show that these strains have been detected globally and in many cases are associated with glycopeptide treatment failure; however, more rigorous clinical studies are required to clearly define the contribution of hVISA to glycopeptide treatment outcomes. It is now becoming clear that sequential point mutations in key global regulatory genes contribute to the hVISA and VISA phenotypes, which are associated predominately with cell wall thickening and restricted vancomycin access to its site of activity in the division septum; however, the phenotypic features of these strains can vary because the mutations leading to resistance can vary. Interestingly, changes in the staphylococcal surface and expression of agr are likely to impact host-pathogen interactions in hVISA and VISA infections. Given the subtleties of vancomycin susceptibility testing against S. aureus, it is imperative that diagnostic laboratories use well-standardized methods and have a framework for detecting reduced vancomycin susceptibility in S. aureus.

show abstract

Section: Potentially Active Antimicrobials Currently Availablementioning

confidence: 99%

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

et al. 2010

View full text Add to dashboard Cite

show abstract

“…It is characterized by rapid concentration-dependent killing and a prolonged antibiotic effect against S. aureus and enterococci [62,63]. In murine neutropenic thigh models of S. aureus meticillin-A c c e p t e d M a n u s c r i p t susceptible [64] or meticillin-resistant strains [65] infection, the AUC/MIC ratio has been correlated with outcome.…”

Section: Daptomycinmentioning

confidence: 99%

Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia

Scaglione

2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Another study found that daptomycin retained good activity against S. aureus with reduced vancomycin susceptibility (1).…”

mentioning

confidence: 99%

Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus

et al. 2005

View full text Add to dashboard Cite

show abstract

Cited by 177 publications

References 18 publications

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia

Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus

Contact Info

Product

Resources

About